Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,018 total articles
Upwork President and CEO Hayden Brown sold 23,745 shares of the company's common stock on March 18, 2026, receiving about $292,343 from those transactions, while also exercising restricted stock units that converted into 46,410 shares the same day. The stock is trading near its 52-week low, and recent corporate moves include matched-or-better-than-…
A reported insider sale at Mohawk Industries saw 6,000 shares change hands on March 19-20, 2026, totaling $581,950. The transactions occurred as the flooring manufacturer's stock hovered near its 52-week low. Mohawk recently reported Q4 2025 results that beat analyst expectations for both adjusted EPS and revenue. InvestingPro analysis cited in rep…
Lizette Benedi Herraiz, General Counsel of Strategic Education, Inc. (NASDAQ: STRA), disposed of 2,982 shares on March 18, 2026 under a Rule 10b5-1 plan, generating proceeds of $238,202. The sale, executed at a weighted average price of $79.88 and occurring within a $79.36 to $80.30 range, follows a quarter in which the company topped EPS and reven…
Ajay Madan Gopal, chief financial officer of TheRealReal, Inc. (NASDAQ: REAL), sold 51,585 shares on March 19, 2026 at $9.29 per share to satisfy withholding taxes related to a performance award. The trade, disclosed on a Form 4 filing, generated $479,224 and left the CFO with 1,179,307 shares. The company recently reported stronger-than-expected f…
Jodi Devlin, TriSalus Life Sciences' Chief of Clinical Operations, sold 3,107 shares of the company's common stock across three transactions between March 11 and March 16, 2026, for a combined $13,171. The trades occurred at prices between $4.09 and $4.13 per share. TriSalus shares are trading below those levels at $3.92 and the company is due to r…
TriSalus Life Sciences Chief Commercial Officer Richard Marshak sold 3,457 shares of the company's common stock across three transactions between March 11 and March 16, 2026, raising $14,209. The disposals were made to satisfy tax withholding obligations tied to vesting restricted stock units and are not characterized as discretionary sales. The co…
Bryan F. Cox, Chief of Research at TriSalus Life Sciences, sold 3,184 shares of the company's common stock across three transactions between March 11 and March 16, 2026, generating about $13,085. The trades were made to satisfy tax obligations tied to vesting restricted stock units and were not discretionary. Cox retains direct ownership of 163,415…
TriSalus Life Sciences Chief Regulatory Officer Jennifer Stevens sold 3,530 shares of common stock across three transactions between March 11 and March 16, 2026, to satisfy tax obligations tied to vested restricted stock units. The sales, executed at prices between $4.09 and $4.13, generated roughly $14,509 in proceeds. The filings note the sales w…
TriSalus Life Sciences CEO Mary T. Szela disposed of 20,302 shares across two trades in March to satisfy tax obligations tied to vesting restricted stock units. The sales, executed on March 11 and March 17, raised $79,382 in aggregate. The moves coincide with mixed corporate results: meaningful revenue growth in Q4 2025 and fiscal 2025, an improved…
Opko Health director John A. Paganelli purchased 10,000 shares of the company's common stock on March 20, 2026, at $1.135 per share, totaling $11,350. The transaction occurs as OPKO shares trade near a 52-week low and follow fourth-quarter results that beat expectations. The company also announced a board appointment to fill a vacancy.
Townsquare Media Executive Vice President of Finance Operations and Technology Scott Schatz sold nearly 29,000 Class A shares on March 19, 2026, for about $147,218 while receiving a separate, immediately vested stock award the day prior. The company recently reported a fourth-quarter 2025 earnings miss and revenue shortfall, and the stock has trade…
Aldeyra Therapeutics director Richard Douglas purchased 70,000 shares on March 19, 2026, investing $98,000 as the stock traded near a 52-week low. The move comes amid regulatory pushback from the FDA over reproxalap and the announced departure of the company's chief development officer. Analysts remain divided on the stock's outlook.
Immunovant Chief Legal Officer Christopher Van Tuyl sold 2,877 shares on March 18, 2026, for $24.97 each, a transaction totaling $71,838 executed to satisfy tax withholding on vested restricted stock units. The shares trade below the sale price at $22.99 but remain about 60% higher than six months ago. The company also reported a third-quarter 2026…
Jane Tunnell, chief marketing officer at Dell Technologies Inc. (NASDAQ:DELL), sold 28,529 shares of Class C common stock on March 18, 2026, in a transaction valued at $4,350,957. The sale comes amid a year of strong equity performance for Dell and concurrent product announcements aimed at expanding the company's AI offerings.
Insmed Chair and CEO William Lewis sold 10,700 shares of company stock on March 19, 2026, generating about $1.5 million, and exercised options to acquire an additional 10,699 shares. The moves leave Lewis with substantive direct and indirect holdings while the company posts robust revenue gains alongside an EPS shortfall and sets aggressive 2026 gu…
Kathleen Goin, chief operating officer of Palvella Therapeutics, sold $507,610 worth of company stock on March 18, 2026. The transaction was carried out under a Rule 10b5-1 plan and coincided with recent company milestones including a $230 million public offering, issuance of a European patent for QTORIN gel, and the launch of a disease-awareness c…
Henry Schein Products CEO Thomas C. Popeck sold 1,355 shares on March 19, 2026, for $72.79 apiece, totaling $98,630 and leaving him with 86,182 shares. The transaction comes as the distributor, trading under NASDAQ: HSIC, posts quarterly results that surpassed EPS and revenue estimates and while management has been actively repurchasing stock. An a…
Richard T. Powers, a director at Esquire Financial Holdings, sold 2,308 shares on March 19, 2026, for $104.825 per share, totaling $241936. The trade occurred amid rising ESQ stock performance and significant corporate activity, including an all-stock acquisition of Signature Bancorporation and a Raymond James upgrade of the shares.
Esquire Financial Holdings director Zises Selig sold 27,000 shares of the company on March 18 and 19, 2026, in transactions totaling $3.18 million. The stock sale came as the bank announced a stock-only acquisition of Signature Bancorporation valued at about $348.4 million, a deal expected to close in the third quarter of 2026. Raymond James has up…
Jeffrey John Neuenschwander, senior vice president and general counsel at CNA Financial, sold 3,287 shares on March 19, 2026, netting $151,103. After the sale he retains 7,277 shares. The company recently reported a fourth-quarter shortfall in both core income and revenue versus analyst estimates, with underwriting performance cited as a weakness. …
Core Molding Technologies COO Eric Palomaki purchased 400 shares of company stock on March 20, 2026, spending $8,020 across two trades. The acquisition comes amid company beat on fourth-quarter 2025 results, an authorized $7.5 million repurchase program, and InvestingPro indicators that management has been active with buybacks and that the stock ma…
Raymond James Financial Chief Administrative Officer Allaire Bella Loykhter sold 29,551 shares on March 19, 2026, for roughly $4.21 million. The transaction leaves her with 53,586 directly held shares and an additional 1,292 shares held indirectly through an ESOP. The sale occurs as Raymond James posts modestly stronger-than-expected adjusted EPS b…
Patrizio Vinciarelli, chairman and chief executive officer of Vicor Corp (NASDAQ:VICR), sold 42,631 shares of the company's common stock on March 19, 2026, in multiple trades that generated roughly $8.9 million. The disposals occurred under a Rule 10b5-1 trading arrangement adopted Nov. 3, 2025. At the time of the sale the stock was trading close t…
Serina Therapeutics Chief Scientific Officer Randall Moreadith sold 39,000 shares of common stock on March 19, 2026, for $2.50 per share, realizing $97,500. On the same day he exercised options to acquire an equal number of shares at $0.06 per share, a transaction valued at $2,340. Following these moves Moreadith holds no direct shares. The sale ca…
A director at Gaia Inc. acquired 2,000 Class A shares on March 18, 2026, spending $6,020 at $3.01 per share. The purchase raises his direct holdings to 306,457 shares. The stock is trading close to its 52-week low after a six-month, 53% slide. Platform valuation analysis pegs a Fair Value of $4.39 and offers additional research resources. Separatel…
